Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug

Seung Ho Lee, Min Ji Sung, Sang June Hahn, Jimok Kim, Gyesik Min, Su Hyun Jo, Han Choe, Bok Hee Choi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This study examined the effect of rosiglitazone, an oral antidiabetic drug, on human ether-a-gogo- related gene (HERG) channels expressed in human embryonic kidney (HEK293) cells. Using the whole-cell patch-clamp technique, interaction between rosiglitazone and HERG in HEK293 cells was studied. Rosiglitazone inhibited HERG channels in a concentration-dependent manner, with an IC50 value of 18.8 μM and a Hill coefficient of 1.0. These effects were reversible after wash-out of the drug. The rosiglitazone-induced inhibition of HERG channels was voltagedependent, with a steep increase in inhibition over the voltage range of channel opening. However, inhibition was voltage-independent over the voltage range in which channels are fully activated. Rosiglitazone did not change the steady-state activation or inactivation curves or the activation or deactivation kinetics, implying that rosiglitazone blocks HERG channels predominantly in the open and inactivated state rather than in the closed state. The present study suggests that rosiglitazone blocks HERG channels by binding to activated and inactivated channels, and rosiglitazone use should thus be carefully monitored in patients with pre-existing QT prolongation.

Original languageEnglish (US)
Pages (from-to)1655-1664
Number of pages10
JournalArchives of Pharmacal Research
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

rosiglitazone
Hypoglycemic Agents
Ether
Genes
HEK293 Cells
Electric potential
Chemical activation
Clamping devices
Patch-Clamp Techniques

Keywords

  • Antidiabetic drug
  • Cardiotoxicity
  • HERG
  • Long QT syndrome
  • Rosiglitazone

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this

Lee, S. H., Sung, M. J., Hahn, S. J., Kim, J., Min, G., Jo, S. H., ... Choi, B. H. (2012). Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug. Archives of Pharmacal Research, 35(9), 1655-1664. https://doi.org/10.1007/s12272-012-0917-x

Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug. / Lee, Seung Ho; Sung, Min Ji; Hahn, Sang June; Kim, Jimok; Min, Gyesik; Jo, Su Hyun; Choe, Han; Choi, Bok Hee.

In: Archives of Pharmacal Research, Vol. 35, No. 9, 01.09.2012, p. 1655-1664.

Research output: Contribution to journalArticle

Lee, SH, Sung, MJ, Hahn, SJ, Kim, J, Min, G, Jo, SH, Choe, H & Choi, BH 2012, 'Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug', Archives of Pharmacal Research, vol. 35, no. 9, pp. 1655-1664. https://doi.org/10.1007/s12272-012-0917-x
Lee, Seung Ho ; Sung, Min Ji ; Hahn, Sang June ; Kim, Jimok ; Min, Gyesik ; Jo, Su Hyun ; Choe, Han ; Choi, Bok Hee. / Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug. In: Archives of Pharmacal Research. 2012 ; Vol. 35, No. 9. pp. 1655-1664.
@article{5bfacf23bfac4084b62724ee4cb208dd,
title = "Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug",
abstract = "This study examined the effect of rosiglitazone, an oral antidiabetic drug, on human ether-a-gogo- related gene (HERG) channels expressed in human embryonic kidney (HEK293) cells. Using the whole-cell patch-clamp technique, interaction between rosiglitazone and HERG in HEK293 cells was studied. Rosiglitazone inhibited HERG channels in a concentration-dependent manner, with an IC50 value of 18.8 μM and a Hill coefficient of 1.0. These effects were reversible after wash-out of the drug. The rosiglitazone-induced inhibition of HERG channels was voltagedependent, with a steep increase in inhibition over the voltage range of channel opening. However, inhibition was voltage-independent over the voltage range in which channels are fully activated. Rosiglitazone did not change the steady-state activation or inactivation curves or the activation or deactivation kinetics, implying that rosiglitazone blocks HERG channels predominantly in the open and inactivated state rather than in the closed state. The present study suggests that rosiglitazone blocks HERG channels by binding to activated and inactivated channels, and rosiglitazone use should thus be carefully monitored in patients with pre-existing QT prolongation.",
keywords = "Antidiabetic drug, Cardiotoxicity, HERG, Long QT syndrome, Rosiglitazone",
author = "Lee, {Seung Ho} and Sung, {Min Ji} and Hahn, {Sang June} and Jimok Kim and Gyesik Min and Jo, {Su Hyun} and Han Choe and Choi, {Bok Hee}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s12272-012-0917-x",
language = "English (US)",
volume = "35",
pages = "1655--1664",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "9",

}

TY - JOUR

T1 - Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug

AU - Lee, Seung Ho

AU - Sung, Min Ji

AU - Hahn, Sang June

AU - Kim, Jimok

AU - Min, Gyesik

AU - Jo, Su Hyun

AU - Choe, Han

AU - Choi, Bok Hee

PY - 2012/9/1

Y1 - 2012/9/1

N2 - This study examined the effect of rosiglitazone, an oral antidiabetic drug, on human ether-a-gogo- related gene (HERG) channels expressed in human embryonic kidney (HEK293) cells. Using the whole-cell patch-clamp technique, interaction between rosiglitazone and HERG in HEK293 cells was studied. Rosiglitazone inhibited HERG channels in a concentration-dependent manner, with an IC50 value of 18.8 μM and a Hill coefficient of 1.0. These effects were reversible after wash-out of the drug. The rosiglitazone-induced inhibition of HERG channels was voltagedependent, with a steep increase in inhibition over the voltage range of channel opening. However, inhibition was voltage-independent over the voltage range in which channels are fully activated. Rosiglitazone did not change the steady-state activation or inactivation curves or the activation or deactivation kinetics, implying that rosiglitazone blocks HERG channels predominantly in the open and inactivated state rather than in the closed state. The present study suggests that rosiglitazone blocks HERG channels by binding to activated and inactivated channels, and rosiglitazone use should thus be carefully monitored in patients with pre-existing QT prolongation.

AB - This study examined the effect of rosiglitazone, an oral antidiabetic drug, on human ether-a-gogo- related gene (HERG) channels expressed in human embryonic kidney (HEK293) cells. Using the whole-cell patch-clamp technique, interaction between rosiglitazone and HERG in HEK293 cells was studied. Rosiglitazone inhibited HERG channels in a concentration-dependent manner, with an IC50 value of 18.8 μM and a Hill coefficient of 1.0. These effects were reversible after wash-out of the drug. The rosiglitazone-induced inhibition of HERG channels was voltagedependent, with a steep increase in inhibition over the voltage range of channel opening. However, inhibition was voltage-independent over the voltage range in which channels are fully activated. Rosiglitazone did not change the steady-state activation or inactivation curves or the activation or deactivation kinetics, implying that rosiglitazone blocks HERG channels predominantly in the open and inactivated state rather than in the closed state. The present study suggests that rosiglitazone blocks HERG channels by binding to activated and inactivated channels, and rosiglitazone use should thus be carefully monitored in patients with pre-existing QT prolongation.

KW - Antidiabetic drug

KW - Cardiotoxicity

KW - HERG

KW - Long QT syndrome

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=84872109571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872109571&partnerID=8YFLogxK

U2 - 10.1007/s12272-012-0917-x

DO - 10.1007/s12272-012-0917-x

M3 - Article

VL - 35

SP - 1655

EP - 1664

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 9

ER -